BRPI1016209A2 - agente de alvejamento de linfócito-b para uso em um método para o tratamento de uma doença - Google Patents
agente de alvejamento de linfócito-b para uso em um método para o tratamento de uma doençaInfo
- Publication number
- BRPI1016209A2 BRPI1016209A2 BRPI1016209A BRPI1016209A BRPI1016209A2 BR PI1016209 A2 BRPI1016209 A2 BR PI1016209A2 BR PI1016209 A BRPI1016209 A BR PI1016209A BR PI1016209 A BRPI1016209 A BR PI1016209A BR PI1016209 A2 BRPI1016209 A2 BR PI1016209A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- treating
- targeting agent
- lymphocyte targeting
- lymphocyte
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09005424 | 2009-04-16 | ||
| PCT/EP2010/002362 WO2010118890A1 (en) | 2009-04-16 | 2010-04-16 | B-lymphocyte targeting agents for use in a method for the treatment of a disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1016209A2 true BRPI1016209A2 (pt) | 2016-11-08 |
Family
ID=42235705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1016209A BRPI1016209A2 (pt) | 2009-04-16 | 2010-04-16 | agente de alvejamento de linfócito-b para uso em um método para o tratamento de uma doença |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10144777B2 (pt) |
| EP (1) | EP2419449A1 (pt) |
| JP (1) | JP5863115B2 (pt) |
| CN (1) | CN102395602B (pt) |
| AU (1) | AU2010237272B2 (pt) |
| BR (1) | BRPI1016209A2 (pt) |
| CA (1) | CA2758585A1 (pt) |
| WO (1) | WO2010118890A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2773221B1 (en) * | 2011-11-04 | 2019-01-09 | Bio-Rad Laboratories, Inc. | Simultaneous purification of cell components |
| US9766207B2 (en) | 2011-11-04 | 2017-09-19 | Bio-Rad Laboratories, Inc. | Affinity methods and compositions employing electronic control of pH |
| EP2814597A4 (en) | 2012-02-15 | 2015-10-28 | Bio Rad Laboratories | ELECTRONIC CONTROL OF PH-VALUE AND ION STRENGTH |
| US9321012B2 (en) | 2012-04-04 | 2016-04-26 | Bio-Rad Laboratories, Inc. | Electronic protein fractionation |
| CN107635585A (zh) * | 2015-03-06 | 2018-01-26 | 分析科学莱布尼茨研究所Isas协会 | 心力衰竭的治疗和预防中的rkip激动 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0932417B1 (en) | 1996-10-17 | 2003-03-05 | Immunomedics, Inc. | Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
| MXPA06011805A (es) * | 2004-04-16 | 2006-12-15 | Genentech Inc | Metodo para aumentar agotamiento de celulas b. |
| US20070009518A1 (en) * | 2005-05-18 | 2007-01-11 | Biogen Idec Inc. | Methods for treating fibrotic conditions |
| MX2007014497A (es) * | 2005-05-20 | 2008-02-07 | Genentech Inc | Pretratamiento de una muestra biologica de un sujeto con enfermedad autoinmune. |
| EP1904101A4 (en) | 2005-06-08 | 2011-06-15 | Univ Duke | ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION |
| CN103694349A (zh) * | 2006-09-08 | 2014-04-02 | 米迪缪尼有限公司 | 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用 |
-
2010
- 2010-04-16 BR BRPI1016209A patent/BRPI1016209A2/pt not_active IP Right Cessation
- 2010-04-16 WO PCT/EP2010/002362 patent/WO2010118890A1/en not_active Ceased
- 2010-04-16 CA CA2758585A patent/CA2758585A1/en not_active Abandoned
- 2010-04-16 JP JP2012505094A patent/JP5863115B2/ja not_active Expired - Fee Related
- 2010-04-16 US US13/264,090 patent/US10144777B2/en not_active Expired - Fee Related
- 2010-04-16 EP EP10713861A patent/EP2419449A1/en not_active Withdrawn
- 2010-04-16 AU AU2010237272A patent/AU2010237272B2/en not_active Ceased
- 2010-04-16 CN CN201080017150.3A patent/CN102395602B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010237272B2 (en) | 2015-07-09 |
| US20120100069A1 (en) | 2012-04-26 |
| AU2010237272A1 (en) | 2011-11-10 |
| CA2758585A1 (en) | 2010-10-21 |
| JP2012524037A (ja) | 2012-10-11 |
| WO2010118890A1 (en) | 2010-10-21 |
| CN102395602A (zh) | 2012-03-28 |
| JP5863115B2 (ja) | 2016-02-16 |
| EP2419449A1 (en) | 2012-02-22 |
| US10144777B2 (en) | 2018-12-04 |
| CN102395602B (zh) | 2017-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0815760A2 (pt) | Composição dermatológica injetável para o tratamento de rugas | |
| BRPI0811589A2 (pt) | Composição farmacêutica e método para tratar câncer | |
| SG10201503135RA (en) | Agent for treating disease | |
| IL207892A0 (en) | Agent for treating disease | |
| BR112012008854A2 (pt) | combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano | |
| IL207891A0 (en) | Agent for treating disease | |
| BRPI0813725A2 (pt) | Métodos e composições para tratamento de doenças | |
| BRPI0919238A2 (pt) | métodos e composições para o tratamento de câncer | |
| BRPI0908503A2 (pt) | partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos | |
| BR112013018679A2 (pt) | agente para o tratamento da alopecia | |
| BRPI0821145A2 (pt) | Agente terapêutico para prurido | |
| BRPI0909164A2 (pt) | método e composições para o tratamento de câncer | |
| BRPI0910760A2 (pt) | método para remineralizar tecido, agente remineralizador, e, kit | |
| BRPI1007972A2 (pt) | composições de combinação e métodos para o tratamento de câncer | |
| BRPI1011325A2 (pt) | composições e métodos para o tratamento de inflamação | |
| BRPI0811059A2 (pt) | combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação | |
| BR112012027145A2 (pt) | emulsão, composição de uso final e método para tratar uma condição cutânea | |
| BRPI1013509A2 (pt) | método e composição para melhorar a absorção de agentes terapêuticos | |
| BRPI0719523A2 (pt) | Derivado de espirocetal de tioglicose e uso deste como agente terapêutico para diabetes | |
| BRPI0918401A2 (pt) | método para seletivamente aquecer uma linha de agente redutor | |
| BRPI0922367A2 (pt) | enzastaurin para o tratamento de câncer | |
| BRPI1016209A2 (pt) | agente de alvejamento de linfócito-b para uso em um método para o tratamento de uma doença | |
| BRPI0810207A2 (pt) | Métodos e composições para o tratamento de câncer | |
| BRPI0907723A2 (pt) | Métodos e composições para o tratamento de doença respiratória | |
| BRPI0918508A2 (pt) | orto-aminoanilidas para o tratamento de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2562 DE 11/02/2020. |